FluoroPharma Medical Stock

FluoroPharma Medical Current Liabilities

The Current Liabilities of FluoroPharma Medical (FPMI) as of Aug 15, 2026 is 10.51 M USD. In the previous year, Current Liabilities was 8.70 M USD — a change of 20.87% (higher).

Current Liabilities

10.51 MUSD

YoY

20.87%

Last updated:

Current Liabilities of FluoroPharma Medical is 2026 10.51 M USD. Current Liabilities of FluoroPharma Medical was 2025 8.70 M USD. It decreases by 20.87% higher compared to the previous year.
Access this data via the Eulerpool API

FluoroPharma Medical Stock analysis

What does FluoroPharma Medical do? FluoroPharma Medical Inc is an innovative company from the USA that specializes in molecular imaging. It was founded in 2003 and is based in Boston, Massachusetts. The company's goal is to improve the diagnosis and treatment of cardiovascular and cancer diseases. The business model of FluoroPharma Medical is based on the development of radioactive tracers that are used in conjunction with imaging techniques such as PET (Positron Emission Tomography). These tracers are typically administered in the form of radiopharmaceuticals and allow real-time tracking of metabolic processes in the body of patients. The information obtained is used by doctors to make diagnoses and optimize treatment. FluoroPharma Medical specializes in the development of tracers specifically for cardiovascular and cancer diseases. These include the tracer BFPET (up to 3 hours), which is used for the diagnosis of coronary heart disease, and the tracer CardioPET (up to 3 hours), which is used for the diagnosis of cardiovascular diseases. In addition, the company is working on other tracers that are intended for the diagnosis of various types of cancer, such as prostate cancer, breast cancer, and lung cancer. FluoroPharma Medical is divided into different divisions to better organize its activities. The Research and Development division is responsible for the development of new tracers and conducting clinical studies. The Production division is responsible for the manufacturing and distribution of radiopharmaceuticals. Marketing and distribution are handled by the Sales and Marketing division, which works closely with doctors and hospitals. The products of FluoroPharma Medical are currently still in the development phase and not commercially available. However, the company is working closely with various universities and medical facilities to test its tracers in clinical trials. The aim is to demonstrate the effectiveness and safety of the tracers and obtain approval from the FDA (Food and Drug Administration). FluoroPharma Medical has established itself as a pioneer in the field of molecular imaging and is committed to further improving the diagnosis and treatment of cardiovascular and cancer diseases. With its innovative tracers and focus on clinical practice, the company has the potential to significantly improve the medical care of patients in the future. FluoroPharma Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FluoroPharma Medical stock

Current Liabilities of FluoroPharma Medical is 10.51 M USD in 2026.

Current Liabilities of FluoroPharma Medical changed from 8.70 M USD to 10.51 M USD, representing a 20.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities FluoroPharma Medical since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's FluoroPharma Medical historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — FluoroPharma Medical

All Key Metrics — FluoroPharma Medical